Clinical Trial

Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to investigate how the duration of fasting and temporary stopping of Glucagon-Like-Peptide 1 (GLP-1) medications affect the amount of food left in the stomach in people using liraglutide (injected), semaglutide (taken by mouth) or semaglutide (injected). The length of participants participation in the study will depend on the type of GLP-1 RA treatment participants are already using.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-06-19 -> 2026-12-13 2026-07-22
minor Completion pushed: 2026-07-17 -> 2027-01-06 2026-07-22
Trial Details
NCT Number NCT07225816
Lead Sponsor Novo Nordisk A/S
Conditions Obesity
Enrollment 71 participants
Start Date 2025-11-07
Primary Completion 2026-12-13 (estimated)
Study Completion 2027-01-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-21